Xing Wang

Xing Wang

Auto-generated profile, based on publicly available information

Xing Wang

Translational Medicine Center, Shanghai General Hospital, Shanghai JiaoTong University School of Medicine 2 , Shanghai, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2023 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
SHShan Huang
Shan Huang
QZQimin Zhang
Qimin Zhang
MZManyu Zhao
Manyu Zhao
XWXing Wang
Xing Wang
YZYilei Zhang
Yilei Zhang
PZPeijing Zhang
Peijing Zhang
The dependency of cancer cells on iron increases their susceptibility to ferroptosis, thus providing new opportunities for patients with treatment-resistant tumors. However, we show that lipid peroxidation, a hallmark of ferroptosis, was found in various areas of patient samples, indicating the potential resistance of ferroptosis. Using whole deubiquitinases (DUBs) sgRNA screening, we found that loss of ZRANB1 confers cancer cell resistance to ferroptosis. Intriguingly, functional studies revealed that ZRANB1 ubiquitinates and represses SLC7A11 expression as an E3 ubiquitin ligase and that ZRANB1 inhibits glutathione (GSH) synthesis through SLC7A11 degradation, leading to elevated lipid peroxidation and ferroptosis. Deletion of the region (residues 463–584) abolishes the E3 activity of ZRANB1. Moreover, we show that ZRANB1 has lower expression in tumors, which is positively correlated with lipid peroxidation. Collectively, our results demonstrate the role of ZRANB1 in ferroptosis resistance and unveil mechanisms involving modulation of E3 ligase activity through an unconventional catalytic domain.